Contrasting of Trevena Inc. (TRVN) and Surface Oncology Inc. (NASDAQ:SURF)

Both Trevena Inc. (NASDAQ:TRVN) and Surface Oncology Inc. (NASDAQ:SURF) are Biotechnology companies, competing one another. We will contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trevena Inc. 5.73M 24.49 30.78M -0.57 0.00
Surface Oncology Inc. 59.42M 2.00 6.61M -0.54 0.00

Table 1 demonstrates Trevena Inc. and Surface Oncology Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 represents Trevena Inc. (NASDAQ:TRVN) and Surface Oncology Inc. (NASDAQ:SURF)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Trevena Inc. -537.17% -94.8% -51.8%
Surface Oncology Inc. -11.12% 63.7% 15.3%


The Current Ratio and Quick Ratio of Trevena Inc. are 4.3 and 4.3 respectively. Its competitor Surface Oncology Inc.’s Current Ratio is 6.4 and its Quick Ratio is 6.4. Surface Oncology Inc. can pay off short and long-term obligations better than Trevena Inc.

Analyst Recommendations

Trevena Inc. and Surface Oncology Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Trevena Inc. 0 1 0 2.00
Surface Oncology Inc. 0 0 0 0.00

The average target price of Trevena Inc. is $1.25, with potential downside of -17.76%.

Institutional & Insider Ownership

The shares of both Trevena Inc. and Surface Oncology Inc. are owned by institutional investors at 26% and 60.3% respectively. Trevena Inc.’s share owned by insiders are 0.8%. Insiders Comparatively, owned 0.3% of Surface Oncology Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Trevena Inc. 4.9% 40.19% 140.5% -5.06% -16.2% 248.84%
Surface Oncology Inc. -2.58% -27.65% -47.41% -54.24% 0% -1.89%

For the past year Trevena Inc. had bullish trend while Surface Oncology Inc. had bearish trend.


On 8 of the 11 factors Surface Oncology Inc. beats Trevena Inc.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.